Massachusetts General Hospital reports on news from the Neurology Service on clinical trials, progress in neuroscience research, and recognition for clinical excellence.

07/15/2014: #1 in New England, #2 in the nation

U.S. News & World Report ranks Massachusetts General Hospital among the top hospitals in America based on our quality of care, patient safety and reputation in 16 specialties.

06/24/2014: NeuroBlast e-Newsletter

NeuroBlast: the newsletter of translational neuroscience and clinical care advances in neurology, neurosurgery, and neuroscience from Massachusetts General Hospital.

06/19/2014: New device brings hope to epilepsy patients

After years of seizures, a new device gives one Mass General epilepsy patient a new lease on life.

06/13/2014: Every second counts

When it comes to treating stroke patients, every second counts.

06/04/2014: Increasing Surgical Options for Epilepsy Patients

NeuroBlast: the newsletter of translational neuroscience and clinical care advances in neurology, neurosurgery, and neuroscience from Massachusetts General Hospital.

06/04/2014: The MGH Epilepsy Service – Where Complexity Meets Innovation

A young Albanian architect found help for his seizure disorders thanks to a unique team of specialists from the Department of Neurology at Massachusetts General Hospital.

05/28/2014: Will New Research Redefine Epilepsy?

Recent research is challenging the traditional definition of epilepsy as an expression of increased excitability and firing of a group of neurons. This has major implications for clinical treatment.

05/27/2014: The MGH Epilepsy Service – Where Complexity Meets Innovation

When Elton, a young Albanian architect, couldn’t find treatment for his disabling seizures in Albania, he traveled 500 miles to Austria to meet with Massachusetts General Hospital (MGH) Epilepsy Service Director Andrew J. Cole, MD. Dr. Cole, in Austria on a business trip, felt Elton was a good candidate for surgery and brought his case back to his colleagues in Boston.

05/14/2014: Mass General recognized for stroke care

Massachusetts General Hospital is the recipient of the 2014 Get With The Guidelines-Stroke Gold-Plus Quality Achievement Award and the Target: Stroke Honor Roll. These awards, sponsored by the American Stroke Association and the American Heart Association, recognize hospitals that provide the highest quality stroke care.

05/09/2014: Supporting Stroke Services

Lee H. Schwamm, MD, executive vice chairman of Neurology, director of the Mass General Stroke Service and a leader in the Mass General Institute for Heart, Vascular and Stroke Care, shares information about strokes, warning signs and advances in stroke care.

04/30/2014: In recognizing speech sounds, the brain does not work the way a computer does

How does the brain decide whether something is correct? When it comes to the processing of spoken language, the theory has been that the brain applies a set of rules to determine which combinations of sounds are permissible. Now the work of MGH investigators suggests that the brain decides based on the words that are already known.

02/27/2014: High-calorie feeding may slow progression of ALS

Increasing the number of calories consumed by patients with amyotrophic lateral sclerosis (ALS) may be a relatively simple way of extending their survival. A phase 2 clinical trial led by Massachusetts General Hospital physicians found that ALS patients receiving a high-calorie, high-carbohydrate tube-feeding formula lived longer with fewer adverse events than participants who received a standard formula designed maintain their weight.

02/07/2014: First Huntington disease prevention trial shows treatment safety, suggests slowing of presymptomatic progression

The first clinical trial of a drug intended to delay the onset of symptoms of Huntington disease reveals that high-dose treatment with the nutritional supplement creatine was safe and well tolerated by most study participants. In addition, neuroimaging provided evidence that creatine might slow the progression of presymptomatic disease.

01/31/2014: Northeast ALS Consortium (NEALS) Website Offers Resources for Patients and Researchers

The Northeast ALS Consortium (NEALS) website is devoted to supporting clinical research of Amyotrophic Lateral Sclerosis (ALS) and other motor neuron disease (MND).

01/30/2014: ALS Clinical Trials Liaison Available to Help Connect PALS With Clinical Research Information

NEALS and ALSA partner to offer clinical trial liaison service to help people with ALS navigate the world of clinical research.

12/23/2013: Inosine treatment safely elevates urate levels in Parkinson disease patients

A clinical trial assessing the potential of the nutritional supplement inosine to treat Parkinson disease has found that the studied dosages successfully raised participants' levels of the antioxidant urate without producing serious side effects.

12/11/2013: Alzheimer’s Disease Gene Discovery & Drug Discovery

“This is the largest collection of familial Alzheimer’s whole-genome sequences in the world,” Dr. Tanzi says, comprising half a petabyte of data, equivalent to the entire contents of the Library of Congress. “This is as big as big data gets.” 

12/10/2013: Spinal Metastases & Stereotactic Radiosurgery

Radiosurgery has shifted the paradigm of treating patients by minimizing the morbidity of conventional surgery and, focusing on tumor control.

12/10/2013: Dietary Therapy for Pediatric Epilepsy

Dietary therapy is prescribed most often for patients with refractory epilepsy, whose seizures have not been controlled despite trying multiple antiepileptic drugs.

12/10/2013: Tau Pathology Spreading out from the Entorhinal Cortex Can be Reversed

Neurofibrillary tangles - largely composed of tau protein- are one of the two pathological hallmarks of Alzheimer’s disease.

12/10/2013: Alzheimer's Early Treatment

Can anti-amyloid antibody treatment reverse Alzheimer’s disease pathology before memory loss sets in?

12/10/2013: Alzheimer’s Preclinical Disease Biomarker

Mark Albers, MD, PhD, is developing a set of simple but powerful tools to screen for the very earliest stages of preclinical Alzheimer’s Disease.

12/10/2013: NeuroBlast e-Newsletter December 2013

In this issue: spinal metastases & stereotactic radiosurgery; skull base tumors & endoscopic surgery; pediatric epilepsy dietary therapy; Alzheimer Disease: tau pathology; drug & gene discovery; early treatment; preclinical diagnostic tools.

12/01/2013: Strides in Understanding and Treating ALS

The Northeast ALS Consortium, co-founded by Massachusetts General Hospital researcher Merit Cudkowicz, MD, has spurred basic and translational research that has led to investigational therapies and improved patient outcomes.

11/20/2013: Study reveals how variant forms of APOE protein impact risk of Alzheimer's disease

A study led by MGH investigators shows that even low levels of the Alzheimer's-associated APOE4 protein can increase toxic amyloid beta brain plaques and the characteristic neuronal damage in mouse models of the disease. Introducing APOE2, a rare, potentially protective variant, reduced amyloid deposits and associated damage.

11/04/2013: Imaging studies may predict tumor response to anti-angiogenic drugs

Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with anti-angiogenic drugs and which will not.

11/01/2013: "The Art of Illness"

Paul S. Russell, MD Museum of Medical History and Innovation invites you to attend its latest lecture in its evening series

10/24/2013: Genetic analysis reveals novel insights into the genetic architecture of obsessive-compulsive disorder, Tourette syndrome

An international research consortium led by investigators at MGH and the University of Chicago has answered several questions about the genetic background of obsessive-compulsive disorder and Tourette syndrome, providing the first direct confirmation that both are highly heritable and also revealing major differences between the underlying genetic makeup of the disorders.

09/24/2013: Study confirms that rare mutations increase risk of late-onset Alzheimer's disease

MGH researchers have identified and validated two rare gene mutations that appear to cause the common form of Alzheimer's disease (AD) that strikes after the age of 60. The two mutations occur in a gene called ADAM10, which now becomes the second pathologically-confirmed gene for late-onset AD and the fifth AD gene overall.

09/10/2013: Ihn Sik Seong: The Long Search for the Full Story of Huntington’s Disease

Understanding the molecular pathogenesis of Huntington’s disease.

08/30/2013: Use of clot-dissolving drug for ischemic stroke nearly doubled from 2003 to 2011.

A team of researchers reports both an overall increase in the use of tPA to dissolve clots blocking arteries supplying the brain and administration of the potentially life-saving drug to a more diverse group of patients.

08/29/2013: Assay shown to be effective in measuring levels of mutant huntingtin protein

An assay designed to measure normal and abnormal forms of the huntingtin protein – the mutated form of which causes Huntington's disease – was successful in detecting levels of the mutant protein in a large multicenter study of individuals at risk for the devastating neurological disorder.

08/28/2013: Anne B. Young, MD, PhD, Fellowship in Therapeutic Development 2014

Applications are being sought for a joint MGH/Biogen Idec two-year training program in translational neuroscience.

08/21/2013: Use of tPA for ischemic stroke nearly doubled from 2003 to 2011

Use of the "clot-busting" drug tissue plasminogen activator (tPA) to treat patients with strokes caused by a blockage of blood flow nearly doubled between 2003 and 2011, but not all eligible patients are receiving the potentially life-saving therapy.

08/16/2013: Neurology Infusion Center: A feeling of family

The MGH Neurology Infusion Center is an ambulatory outpatient unit that delivers infusion and intravenous (IV) services to patients, ages 18 and older, who have a variety of neurological disorders. On average, the unit sees 12 to 14 patients per day but more referrals from MGH clinicians for ambulatory patients are welcome.

07/31/2013: A brain cancer "warrior" takes the trip of a lifetime

Mass General patient Michelle Beale's journey started with debilitating headaches. Now she's traveling around the world.

07/30/2013: Study finds evidence of nerve damage in around half of fibromyalgia patients

About half of a small group of patients with fibromyalgia – a common syndrome that causes chronic pain and other symptoms – was found to have damage to nerve fibers in their skin and other evidence of a disease called small-fiber polyneuropathy, a disorder that sometimes can be treated.

07/23/2013: Digital PCR technology detects brain-tumor-associated mutation in cerebrospinal fluid

MGH researchers and their colleagues have used digital versions of a standard molecular biology tool to detect a common tumor-associated mutation in the cerebrospinal fluid of patients with brain tumors.

07/22/2013: Concussion

When neurosurgeon Tina Duhaime, MD, of the MGH Youth Sports Concussion Clinic, talks with families about concussion, she takes time to explain what is known, and just as importantly, what isn’t known, about this common injury.

07/22/2013: TeleStroke: Real-time Resources for Better Patient Care

Through the TeleStroke network, 30 emergency departments across the northeast have real-time access to stroke experts 24 hours a day, seven days a week.

07/22/2013: E Pluribus Unum for Parkinson Disease - Researchers Draw on Sources to Improve Treatment of PD

What do Gaucher’s disease, gout, and amyloid plaques have in common? For researchers at the MGH, each of them may shed light on the causes and treatment of Parkinson’s disease.

07/22/2013: NeuroBlast e-Newsletter

NeuroBlast: the newsletter of translational neuroscience and clinical care advances in neurology, neurosurgery, and neuroscience from Massachusetts General Hospital.

07/16/2013: #1 in New England, #2 in the nation

U.S. News & World Report ranks Massachusetts General Hospital among the top hospitals in America based on our quality of care, patient safety and reputation in 16 specialties.

06/28/2013: It takes a team

The MGH Acute Stroke Care Team was honored with the 2012 Acute Stroke Champion Award at the MGH Acute Stroke Gala Breakfast.

06/17/2013: Study finds significant racial and ethnic disparities in usage of specialty services for children with autism

A study from investigators at MassGeneral Hospital for Children found that African-American or Hispanic children diagnosed with autism were significantly less likely than white children to have received subspecialty care or procedures related to conditions that often accompany autism spectrum disorders.

06/17/2013: Rare genomic mutations found in 10 families with early-onset, familial Alzheimer's disease

MGH researchers have discovered a type of mutation known as copy-number variants – deletions, duplications, or rearrangements of human genomic DNA – in affected members of 10 families with early-onset Alzheimer's. These are the first new early-onset familial Alzheimer’s disease gene mutations to be reported since 1995.

04/25/2013: Alzheimer's risk gene presents potential treatment target

MGH investigators have determined that one of the recently identified genes contributing to the risk of late-onset Alzheimer's disease regulates the clearance of the toxic amyloid beta (A-beta) protein that accumulates in the brains of patients with the disease.

04/18/2013: Three Mass. General researchers among recipients of Top 10 Clinical Research Achievement awards

Three projects led by Massachusetts General Hospital (MGH) investigators have been named among the Clinical Research Forum's Top 10 Clinical Research Achievements of 2012.

04/12/2013: Mass. General Neurological Clinical Research Institute and Prize4Life receive Bio-IT World Award for creation of ALS data platform

The MGH Neurological Clinical Research Institute and Prize4Life, an organization dedicated to accelerating discovery of treatments and a cure for ALS, received a Best Practices Award at the 2013 Bio-IT World Conference & Expo for their creation of PRO-ACT ,the largest database of information from ALS clinical trials and patient care.

04/03/2013: Phase 1 ALS trial is first to test antisense treatment of neurodegenerative disease

The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis – blocking production of a mutant protein that causes an inherited form of the progressive neurodegenerative disease – may be a first step towards a new era in the treatment of such disorders.

03/20/2013: Mass General receives top honor for stroke patients’ quality of care

Massachusetts General Hospital (MGH) has received a top honor from the Massachusetts Department of Public Health (DPH) for its commitment to improving its quality of care to stroke patients. The “2013 Stroke Collaborative Reaching for Excellence (SCORE) Defect-Free Care Award” recognizes the MGH for providing defect-free care to more than 80 percent of patients admitted with stroke over the course of a year

03/14/2013: Informatics Core at MIND: Building Tools, Creating Connections

The Informatics Core at MIND offers state-of-the-art bioinformatics services, connecting researchers with tools, each other, and expertise to manage their clinical and research databases.

03/11/2013: Nerve damage may underlie widespread, unexplained chronic pain in children

Study finds that most of a group of young patients seen at Mass General for chronic, unexplained pain had test results indicating small-fiber polyneuropathy, a condition not previously reported in children.

01/25/2013: Lessons learned through pages turned

When it came time for Bryn Seltzer, 13, of Needham, to choose her bat mitzvah project, she knew she wanted to give back to the Pediatric Epilepsy Program at MassGeneral Hospital for Children (MGHfC), which had cared for her since she was 6 years old.

01/14/2013: Impaired coordination of brain activity in autism involves local, as well as long-range, signaling

A new study finds that local functional connectivity of the brain – the extent to which activity within a small brain region appears to be coordinated – is reduced in individuals with autism spectrum disorders. It had been believed that local connectivity was increased in the brains of autistic individuals while long-range connectivity was reduced.

12/17/2012: Genetic manipulation of urate alters neurodegeneration in mouse model of Parkinson's disease

A study by MGH researchers adds further support to the possibility that increasing levels of urate may protect against Parkinson's disease. The investigators report that mice with a genetic mutation increasing urate levels were protected against Parkinson's-like neurodegeneration, while the damage was worse in animals with abnormally low urate.

12/06/2012: Combining two genome analysis approaches supports immune system contribution to autism

Researchers using novel approaches and methodologies of identifying genes that contribute to the development of autism have found evidence that disturbances in several immune-system-related pathways contribute to development of autism spectrum disorders.

11/29/2012: Enzyme inhibition protects against Huntington's disease damage in two animal models

Treatment with a novel agent that inhibits the activity of SIRT2, an enzyme that regulates many important cellular functions, reduced neurological damage, slowed the loss of motor function and extended survival in two animal models of Huntington's disease.

10/26/2012: Cure Alzheimer’s Fund donates $5.4 million

On Oct. 18, at a press conference in Cambridge, the Cure Alzheimer’s Fund announced a fitting $5.4 million contribution to the MGH to fund state-of-the-art whole genome DNA sequencing that aims to enhance understanding of the genetic roots of Alzheimer’s.

10/23/2012: Massachusetts General Hospital Launches Angelman Syndrome Clinic

The Angelman Syndrome Clinic, one of only two in the country, will work to reduce the frequency and severity of Angelman syndrome symptoms, particularly seizures, and to develop dietary regimens for individuals that further assist in the reduction of symptoms.

10/18/2012: $5.4 Million Awarded for Research to Guide Alzheimer's Drug Development

Understanding who is most susceptible to Alzheimer's disease and developing early detection models, effective therapies and possibly a cure, is the goal of the largest single private scientific grant ever invested in Alzheimer's Whole Genome Sequencing focused on families afflicted with the disease.

10/05/2012: New neurology chief shares lessons

The 15th Annual Women in Medicine Month Celebration on Sept. 20 featured a keynote lecture by Merit Cudkowicz, MD, chief of Neurology.

09/14/2012: New Mass General Center to Help Speed Development of Neurological Treatments

Mass General received a $20 million grant to establish a nationwide clinical coordinating center for testing drugs that can help people with diseases of the brain such as Alzheimer’s disease.

08/14/2012: First genome-wide association studies of obsessive-compulsive disorder and Tourette syndrome published

Two papers that will appear in the journal Molecular Psychiatry, both receiving advance online release, may help identify gene variants that contribute to the risks of developing obsessive-compulsive disorder or Tourette syndrome.

08/10/2012: Boosting metabolism at work

Research has shown that sitting for extended periods may not only negatively affect health but also may prematurely shorten lifespan. Marie Pasinski, MD, offers five ways to incorporate more activity into the workday.

07/17/2012: Massachusetts General Hospital Ranked #1 in the Nation on U.S. News & World Report Honor Roll

Massachusetts General Hospital has moved into the number one spot on the 2012-13 U.S. News & World Report’s “America’s Best Hospitals” list.

07/16/2012: All’s Quiet on the Lunder Floors

The Lunder Building is leading a noise-reduction revolution. Thanks to careful planning and innovative thinking, patients rest and receive treatment in a quiet healing environment.

05/31/2012: Not Your Typical Rash: Why Shingles Can’t Be Taken Lightly

Anne Louise Oaklander, MD, PhD, associate professor of Neurology, says shingles and post-herpetic neuralgia (PHN), a serious neurological complication in which pain lingers in an area of previous shingles long after the rash heals, cannot be taken lightly. PHN can last for months or years and is a source of severe and disabling pain, particularly for older patients.

05/25/2012: Mind over matter

Nearly 15 years after a stroke left her paralyzed and unable to speak, 59-year-old Cathy Hutchinson controlled a robotic arm to lift coffee to her mouth and take a drink by thinking about moving her own arm.

05/25/2012: 2012 Research Scholars announced

The second group of MGH Research Scholars – recipients of unrestricted five-year grants to support innovative investigations – was announced at the hospital’s Research Advisory Council (RAC) annual meeting on May 11.

05/23/2012: Study supports urate protection against Parkinson's disease, hints at novel mechanism

Use of the antioxidant urate to protect against the neurodegeneration caused by Parkinson's disease appears to rely on more than urate's ability to protect against oxidative damage.

05/16/2012: People with paralysis control robotic arms using brain-computer interface

A new study in Nature reports that two people with tetraplegia were able to reach for and grasp objects in three-dimensional space using robotic arms that they controlled directly with brain activity.

05/04/2012: Responsibility with a smile

In her 30 years as a member of the Child Neurology Department, Ginny Tosney-Trask has “become legendary for her humanity, warmth and generosity.”

04/20/2012: In Memoriam: C. Miller Fisher, MD

C. Miller Fisher, MD, founder of the MGH Stroke Service and widely regarded as the father of stroke neurology, died April 14 at the age of 98.

03/30/2012: Study supports using virtual environment to teach mind/body techniques

A small study from MGH researchers found that online virtual communities may be an effective way to train patients in meditation and other mind/body techniques. The ability to learn and practice approaches that elicit the relaxation response in a virtual environment could help surmount several barriers that can restrict participation.

03/23/2012: Appointments announced

THE MGH WILL WELCOME new chiefs for the Department of Neurology and the Department of Urology later this spring.

12/18/2011: Increased expression of regulatory enzyme may protect against neurodegeneration in Huntington's disease

Treatment that increases brain levels of an important regulatory enzyme may slow the loss of brain cells that characterizes Huntington's disease and other neurodegenerative disorders.

11/24/2011: Rebuilding the Brain’s Circuitry

Neuron transplants have repaired brain circuitry and substantially normalized function in mice with a brain disorder, an advance indicating that key areas of the mammalian brain are more reparable than was widely believed.

11/20/2011: Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial

Treatment with dexpramipexole – a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy – appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease.

10/03/2011: Biomarker for Huntington's disease identified

In a new research paper BWH and MGH researchers identify a transcriptional biomarker that may assist in the monitoring of Huntington's disease activity and in the evaluation of new medications.

09/20/2011: Christopher J. McDougle named director of the Lurie Center for Autism

Christopher J. McDougle, MD has been named director of the Lurie Center for Autism at Massachusetts General Hospital and MassGeneral Hospital for Children.

07/19/2011: MGH ranks #2 in nation

MGH ranks #2 in 2011-2012 U.S. News & World Report "Best Hospitals" rankings

07/01/2011: Care redesign teams move forward with recommendations

The Partners Strategic Initiative is an ongoing effort to improve care and increase efficiency across all Partners institutions, including the MGH.

06/23/2011: Rare genetic disorder provides unique insight into Parkinson’s disease

MGH investigators may have found the mechanism behind a previously reported link between the rare genetic condition Gaucher disease and the common neurodegenerative disorder Parkinson's disease.

06/10/2011: Third Annual Tarbell Lecture features Anne B. Young, MD, PhD

MGH Hotline 6.10.11 A world-renowned neurological researcher and clinician who has helped break down barriers for women in her field, Anne B. Young, MD, PhD, chief of the Department of Neurology, has a great deal of wisdom and insight to offer to colleagues.

05/11/2011: Mild obesity appears to improve survival in ALS patients

Patients with amyotrophic lateral sclerosis (ALS) may be an exception to the rule that being overweight is a health hazard. In a retrospective study of over 400 ALS patients, MGH researchers found that those who were mildly obese survived longer than patients who were normal weight, underweight or even overweight.

04/13/2011: Differences in brain structure indicate risk for developing Alzheimer's disease

Subtle differences in brain anatomy among older individuals with normal cognitive skills may be able to predict both the risk of developing Alzheimer's disease in the following decade and how quickly symptoms of dementia would develop.

04/08/2011: Anne Young, MD, PhD, donates $1M to Department of Neurology

ANNE YOUNG, MD, PHD, chief of Neurology, made history for women in academic medicine by making a $1 million gift to the Department of Neurology through a deferred charitable gift annuity.

03/27/2011: Advanced technology reveals activity of single neurons during seizures

The first study to examine the activity of hundreds of individual human brain cells during seizures has found that seizures begin with extremely diverse neuronal activity, contrary to the classic view that they are characterized by massively synchronized activity.

03/24/2011: BrainGate neural interface system reaches 1,000-day performance milestone

An investigational implanted system being developed to translate brain signals toward control of assistive devices has allowed a woman with paralysis to accurately control a computer cursor at 2.7 years after implantation, providing a key demonstration that neural activity can be read out and converted into action for an unprecedented length of time.

03/11/2011: Lunder Building patient floors enhance patient- and family-oriented care

The top five floors of the Lunder Building are dedicated adult inpatient units for neuroscience and cancer patients. While the patient floors follow a standard design, each has highlights specific to a particular patient population. This week, MGH Hotline will highlight unique features of Floors 6 through 8, which are devoted to neuroscience patients, and provide a general description of a Lunder Building inpatient room. A subsequent issue will focus on Floors 9 and 10, which are dedicated to cancer patients, and will highlight the Lunder Building’s nursing, support services and common areas.

03/03/2011: Brain rhythm predicts real-time sleep stability, may lead to more precise sleep medications

A new study finds that a brain rhythm considered the hallmark of wakefulness not only persists inconspicuously during sleep but also signifies an individual's vulnerability to disturbance by the outside world.

02/18/2011: Lunder Building to “Go Live” this summer

MGH Hotline 2.18.11 In preparation for the summertime transition of several hospital programs and services to the Lunder Building, the MGH Go Live Group for the new facility was established under the auspices of Jean Elrick, MD, senior vice president for Administration.

02/10/2011: Tumor microvesicles reveal detailed genetic information

The MGH research team that previously discovered tumor-associated RNA in tiny membrane-enclosed sacs released into the bloodstream by cancer cells has now found that these microvesicles also contain segments of tumor DNA, including so-called "jumping genes" that copy and insert themselves into other areas of the genome.

02/04/2011: Acute Stroke Quality Task Force recognizes fastest treatment time

MGH Hotline 02.04.11 TIME IS BRAIN when it comes to treating stroke.

01/10/2011: Statin risks may outweigh benefits for patients with a history of brain hemorrhage

A computer decision model suggests that for patients with a history of bleeding within the brain, the risk of recurrence associated with statin treatment may outweigh the benefit of the drug in preventing cardiovascular disease, according to a report posted online today that will appear in the May print issue of Archives of Neurology.

08/09/2010: Brain rhythm predicts ability to sleep through a noisy night

People who have trouble sleeping in noisy environments often resort to strategies like earplugs or noise-canceling headphones that muffle the sound, but a new study from MGH investigators may lead to ways to block disturbing sounds within the brain.

07/16/2010: MGH ranks among top

The MGH ranked third among the country's top hospitals on the annual list of "America's Best Hospitals" issue of U.S. News & World Report.

07/16/2010: MGH residents and fellows make great save during soccer game

SPAIN MAY HAVE WON the World Cup, but a team of MGH medical residents and fellows had a victory of their own on the soccer field this summer when they helped save the life of another player.

05/28/2010: Overcoming the odds

MGH Hotline 5.28.10

05/17/2010: New study characterizes cognitive and anatomic differences in Alzheimer’s disease gene carriers

In the most comprehensive study to date, neurologists have clearly identified significant differences in the ways that Alzheimer’s disease (AD) affects patients with and without the apolipoprotein E ε4 gene, a known genetic risk factor for the neurodegenerative disease.

03/22/2010: Blacks less likely than whites, Hispanics to get evidence-based stroke care

Blacks hospitalized with the most common type of stroke are less likely than white or Hispanic patients to receive evidence-based stroke care, according to a new study in Circulation: Journal of the American Heart Association.

03/10/2010: Surviving a brain stem stroke

Stroke is one of the leading causes of serious, long-term disability in the United States. The Stroke Service at the Massachusetts General Hospital Vascular Center successfully treat one of emergency medicine’s toughest stroke cases.

03/02/2010: Alzheimer's-associated protein may be part of the innate immune system

Amyloid-beta protein – the primary constituent of the plaques found in the brains of Alzheimer's disease patients – may be part of the body's first-line system to defend against infection. In their report in the March 3 issue of PLoS One, a team led by MGH researchers describe their evidence that amyloid-beta protein is an antimicrobial peptide.

03/02/2010: Mass. General Researchers Seek Participants for Parkinson’s Disease Clinical Trial

Researchers at Massachusetts General Hospital are seeking recently diagnosed Parkinson's disease (PD) patients to participate in a clinical trial investigating whether inosine taken to raise the body’s level of urate — a naturally occurring antioxidant — can be used to slow the progress of PD.

01/07/2010: Cutting-edge research, industry-changing model of care improves the lives of patients

Duchenne muscular dystrophy (DMD) is the most prevalent and aggressive type of muscular dystrophy, affecting one in every 3,500 live male births in the world. It is also one of the most common lethal genetic diseases of children worldwide.

12/16/2009: New Web Tool May Help Predict Risk of Second Stroke

Scientists have developed a new web-based tool that may better predict whether a person will suffer a second stroke within 90 days of a first stroke.

10/12/2009: Study supports possible role of urate in slowing Parkinson’s disease progression

By examining data from a 20-year-old clinical trial, a research team based at the MassGeneral Institute for Neurodegenerative Diseases and Harvard School of Public Health, has found evidence supporting the findings of their 2008 study – that elevated levels of the antioxidant urate may slow the progression of Parkinson’s disease.

10/02/2009: In Memoriam: Lisa Krivickas, MD

MGH Hotline 10.02.09 Lisa Krivickas, MD, associate chief of the MGH Department of Physical Medicine and Rehabilitation and a physician in the Department of Neurology, died of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, Sept. 22 at the age of 45.

09/09/2009: MassGeneral Hospital for Children study explains some mysteries of neonatal seizures

A study led by MassGeneral Hospital for Children investigators is providing new insight into the mechanism of neonatal seizures, which have features very different from seizures in older children and adults.

07/21/2009: Tuberous Sclerosis Complex

The Carol and James Herscot Center for Tuberous Sclerosis Complex (TSC) at Massachusetts General Hospital and MassGeneral Hospital for Children is using genetic research to better understand TSC and other diseases like cancer, autism and obesity.

07/08/2009: Antiangiogenesis treatment improves hearing in some NF2 patients

Treatment with the angiogenesis inhibitor bevacizumab improved hearing and alleviated other symptoms in patients with neurofibromatosis type 2 (NF2). The study by researchers from Massachusetts General Hospital (MGH) represents the first report of a successful NF2 treatment not involving surgery or radiation.

06/15/2009: Turning thoughts into action

Dr. Leigh Hochberg from the Department of Neurology at Massachusetts General Hospital is using neurotechnology to harness brain signals that accompany movement. The ultimate goal of the work is to "turn thought into action," with the hope of one day assisting people with ALS, spinal cord injury and stroke to regain control over their environment.

05/26/2009: Mass. General’s Rudy Tanzi a “Rock Star of Science”

Alzheimer’s disease researcher Rudolph Tanzi, PhD, of Massachusetts General Hospital adds another distinction to his scientific career when he joins Aerosmith’s Joe Perry and other rock celebrities in a designer menswear photo shoot as a “Rock Star of Science” in the June issue of GQ Magazine.

05/18/2009: Videoconferencing can increase patient access to stroke specialists

Massachusetts General Hospital neurologist Dr. Lee Schwamm leads a national policy endorsing telestroke as an effective means of stroke evaluation.

05/08/2009: Videoconferencing can increase patient access to stroke specialists

High-quality videoconferencing can increase patient access to stroke specialists; and a transient ischemic attack, once known as a “mini” or “warning” stroke, should be treated with the same urgency as a full-blown stroke, according to two separate statements published today in Stroke.

04/02/2009: Modification of mutant huntingtin protein increases its clearance from brain cells

A new study has identified a potential strategy for removing the abnormal protein that causes Huntington’s disease from brain cells, which could slow the progression of the devastating neurological disorder.

02/26/2009: Alzheimer’s-associated plaques may have impact throughout the brain

The impact of the amyloid plaques that appear in the brains of patients with Alzheimer’s disease may extend beyond the deposits’ effects on neurons– the cells that transmit electrochemical signals throughout the nervous system.

02/26/2009: International collaboration identifies new gene associated with ALS

A collaborative research effort spanning nearly a decade between researchers at Massachusetts General Hospital and King’s College London has identified a novel gene for inherited amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease).

12/19/2008: Home for Christmas

One year ago, a team of intensive care experts at Massachusetts General Hospital collaborated to save Karla Leavenworth's life.

09/15/2008: New screening tool for identifying major depression in patients with epilepsy

Commentary on NDDI-E screening tool for detecting symptoms of major depression, while excluding adverse effects of antiepileptic drugs or temporal lobe epilepsy memory problems

09/23/2013: The Lancet: Neurology

Dexpramipexole vs placebo for patients with ALS (EMPOWER): a randomised, double-blind, phase 3 trial
In a phase III trial, dexpramipexole was generally well tolerated but did not differ from placebo on any pre-specified efficacy endpoint measurement. The trial can inform the design of future clinical research strategies in amyotrophic lateral sclerosis.

12/15/2012: MIND Research Review

MIND Research Review 2012
A review of research at the Massgeneral Institute for Neurodegenerative Disease.
Join our mailing list.

05/16/2012: Amyotrophic Lateral Sclerosis

Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral scle
Published Phase II results demonstrated that single oral doses of 250 mg and 500 mg of CK-2017357 appeared safe and well-tolerated in patients with ALS.

03/13/2012: Stem Cells

Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial i
The results of an ongoing Phase I trial of intraspinal injections of fetal-derived neural stems cells in patients with ALS.

MGH Fund Update Summer 2011
09/01/2011: MGH Fund Update Summer 2011

View this publication
The MGH Fund Update is a publication for supporters of the MGH Fund, Mass General's fundamental resource for providing life-saving patient care, advancing biomedical research, and creating healthcare solutions in our community and around the globe.

05/23/2010: Therapy Times

Tuesdays With an SLP
Paige Nalipinski, senior speech language pathologist and project coordinator at MGH, writes about ALS care guidelines and her experience working with patients at the MGH ALS Multidisciplinary Clinic.

05/01/2010: Lancet Neurology

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral scl
Double-blind, placebo-controlled trial with a time-to-event design assessing the safety and efficacy of lithium in combination with riluzole in patients with ALS.

11/01/2009: Dystonia Newsletter 2009

Dystonia Newsletter 2009
The “Dystonia Update” is an annual newsletter from the research laboratories of Xandra O. Breakefield, PhD and Nutan Sharma, MD, PhD about dystonia research at Massachusetts General Hospital. In the newsletter you will learn about ongoing research projects and the people behind dystonia research, and find answers to commonly asked questions.

07/01/2008: Muscle & Nerve

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.
Safety, tolerability, and pharmacokinetics of arimoclomol in ALS were assessed.

12/01/2007: Dystonia Update Annual Newsletter

Dystonia Newsletter 2007
The “Dystonia Update” is an annual newsletter from the research laboratories of Xandra O. Breakefield, PhD and Nutan Sharma, MD, PhD about dystonia research at Massachusetts General Hospital. In the newsletter you will learn about ongoing research projects and the people behind dystonia research, and find answers to commonly asked questions.

12/15/2006: Dystonia Update 2006

Dystonia Update 2006
The “Dystonia Update” is an annual newsletter from the research laboratories of Xandra O. Breakefield, PhD and Nutan Sharma, MD, PhD about dystonia research at Massachusetts General Hospital. In the newsletter you will learn about ongoing research projects and the people behind dystonia research, and find answers to commonly asked questions.

12/01/2006: Dystonia Newsletter 2006

Dystonia Newsletter 2006
The “Dystonia Update” is an annual newsletter from the research laboratories of Xandra O. Breakefield, PhD and Nutan Sharma, MD, PhD about dystonia research at Massachusetts General Hospital. In the newsletter you will learn about ongoing research projects and the people behind dystonia research, and find answers to commonly asked questions.

07/01/2006: Annals of Neurology

Trial of celecoxib in amyotrophic lateral sclerosis
A double-blind, placebo-controlled, clinical trial to determine if celecoxib is safe and effective in ALS.

12/13/2005: Neurology

Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS
An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS.

11/09/2004: Neurology

A clinical trial of creatine in ALS
A randomized double-blind, placebo controlled trial on 104 patients with ALS from 14 sites to evaluate the efficacy of creatine supplementation in ALS.

08/26/2003: Neurology

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis
A double-blind, placebo-controlled, multicenter randomized clinical trial to determine if long-term topiramate therapy is safe and slows disease progression in patients with ALS.

06/07/2014: MGH ALS Symposium

Please join us for an open exchange of data and ideas to help us succeed in our mission to find cures for ALS and provide excellence in care for people and their families with ALS.

06/07/2014: Moving beyond Mobility: Non-Motor Symptoms of Parkinson’s Disease

Parkinson’s Disease Patient and Caregiver Symposium

12/10/2013: MGH Russell Museum Lunchtime Lecture Series

Paul S. Russell, MD Museum of Medical History and Innovation invites you to attend its latest lecture in its lunchtime series

11/12/2013: "The Art of Illness"

The Massachusetts General Hospital Paul S. Russell, MD Museum of Medical History and Innovation Lecture Series invites you to attend the next in its series of free monthly evening lectures.

07/18/2013: Neurology Grand Rounds

Neurology Grand Rounds are held in the Ether Dome on Thursdays 9:00 am to 10:00 am.

05/18/2013: 3rd Annual Christopher Leavitts Memorial Motorcycle Ride

Join us for the 3rd Annual Christopher Leavitts Memorial Motorcycle Ride on Saturday, May 18th in Everett, to benefit head trauma research at Mass General.

03/06/2013: Beautiful Brain with Marie Pasinski, MD

Harvard neurologist, Dr. Marie Pasinski, MD will talk about keeping your brain healthy.

01/01/2012: Continuing Medical Education in Neurology

The Neurology Service at Mass General offers Continuing Medical Education through Harvard Medical School.

Parkinson's Symposium at MIND- 2008

Momentum in our Pursuit of Cures - Research advances in Parkinson's, Lewy Body dementia, and Parkinson's-Plus disorders. Anne B. Young, MD, PhD, Director, MassGeneral Institute for Neurodegenerative Disease (MIND), formerly Chief of Neurology Service.

Michael Jaff, DO, explains how knowing your personal and family history may help prevent a stroke

Michael Jaff, DO, Medical Director of the Massachusetts General Hospital Fireman Vascular Center explains how carotid artery disease can cause a stroke, unless it is found early and treated, and how you can identify your risk for this condition.

Guy Rordorf, MD, recommends an imaging test for anyone with a family history of FMD

Guy Rordorf, MD, vascular neurologist at the Massachusetts General Hospital Fireman Vascular Center, says an imaging test can detect fibromuscular dysplasia (FMD), and recommends it for those with a family history of the condition. Learn more about FMD and how it weakens artery walls and can lead to severe hypertension or stroke.

Learn more about MIND

The Mass General Institute for Neurodegenerative Disease (MIND) is poised to change the future for people with Alzheimer’s, ALS (Lou Gehrig’s), Huntington’s, and Parkinson’s diseases. Discover MIND and see what we are doing to accelerate research discoveries that will lead to treatment and cures for memory, movement, and neuromuscular disorders.

Celebrating 200 Years: 1811 - 2011

Since 1811, people have counted on Mass General for answers, innovations and medical leadership. As our third century dawns, we remain ready to serve.

The Clinical Trial of Ceftriaxone in ALS

A webinar recording explaining the design and scientific rationale behind the Clinical Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease.

Ceftriaxone Trial Video

A video explaining the design and scientific rationale behind the Clinical Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease.

Neurology Bicentennial Celebration, 2011 Part I

Neurology Bicentennial Celebration, October 13, 2011. Past History of MGH Neurology; Overview of MGH Neurology; Telestroke and Acute Stroke Service; Neurodegenerative Disorders; Pediatric Neurology.

Neurology Bicentennial Celebration, 2011 Part II

Neurology Bicentennial Celebration, October 13, 2011. Clinical and research presentations on ALS, Stroke, Alzheimer’s Disease, and Parkinson’s Disease

Neurology Bicentennial Celebration 2011 II HD

Neurology Bicentennial Celebration, October 13, 2011. Clinical and research presentations on Huntington’s Disease, Epilepsy, and Neuro-Oncology.

Respiratory Assistance Video

A video for ALS patients discussing and demonstrating uses of bipap and cough assist machines.

A young stroke victim experiences a dramatic recovery

A young stroke victim experiences a dramatic recovery from a life threatening basilar artery occlusion with the help of the Acute Stroke Team and Dr. Aneesh Singhal. Also featuring Dr. Lee Schwamm.

Treatment for epileptic seizures in young patient

Treatment for epileptic seizures with Dr. Thiele and brain surgery performed by Dr. Duhaime help this young epileptic patient regain normalcy after experiencing up to 12 seizures daily.

A young man recovers from seizures and coma

The Neuro Critical Care Team’s excellence in service and innovation bring a young man back to life after epileptic seizures leave him comatose for five months. Features Dr. Rosand and Dr. Cole.

Patient diagnosed with Frontal Temporal Dementia

A gripping story of a young man diagnosed with Frontal Temporal Dementia by Dr. Brad Dickerson.

Community Health

MGH doctors Nicte Mejia-Gonzalez and Marie Pasinski talk about providing neurological care to patients at MGH Community Health Care centers.

Partners Neurology Residency

Neurology residents, program graduates, faculty members, and the education director talk about training at Mass General Hospital and Brigham and Women’s Hospital.

Epilepsy: The Road to a Cure

A young man's quest to find a cure for his epileptic seizures takes him on a journey from Albania to Boston.

ALS Patient Video

Nicole from Boston, shares her story about her battle with ALS and her strong desire to help others with the disease in the future. Mass General's ALS Multidisciplinary Clinic provides the latest treatments and research opportunities for people with Amyotrophic Lateral Sclerosis.

Patient Welcome from Dr. Cudkowicz

Dr. Merit Cudkowicz, Neurology's Chief of Service, shares what makes the Mass General ALS Multidisciplinary Clinic so special.

Acute Stroke Care: When Time is Critical

13 days after giving birth to her son, a young woman suffers a stroke and makes a miraculous recovery. Features Dr. Leslie-Mazwi, Dr. Mehta and Dr. Musolino.

Acute Stroke Care: When Time is Critical

13 days after giving birth to her son, a young woman suffers a stroke and makes a miraculous recovery. Features Dr. Leslie-Mazwi, Dr. Mehta and Dr. Musolino.Acute Stroke Care: When Time is Critical

Congratulations to Dr. Merit Cudkowicz for receiving the MDA LOU GEHRIG HUMANITARIAN AWARD

Congratulations to Dr. Merit Cudkowicz, MGH Neurology Department Chairperson and Director, MGH ALS Clinic, for receiving the MDA LOU GEHRIG HUMANITARIAN AWARD. This award is given to a researcher, physician, or clinician who supports MDA/ALS research initiatives and clinical services and continues to fight the battle against ALS. View her acceptance speech where she discusses reasons for hope in the future of ALS treatments.